Eyes on sales of blockbuster drugs Eylea, Dupixent for Regeneron's Q2 2022 earnings
mohd izzuan

Regeneron Pharmaceuticals (NASDAQ:REGN) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open.
The consensus EPS Estimate is $8.75 (vs. $25.80 last year) and the consensus Revenue Estimate is $2.8B (vs. $5.14B last year).
The significantly lower estimates compared to the year-ago figures is primarily due to the fact that sales of Regeneron's (REGN) COVID-19 antibody cocktail, REGEN-COV, are expected to be negligible this quarter. In last year's Q2, REGN recognized $2.59B of REGEN-COV sales under an agreement with the U.S. government.
The U.S. FDA in January this year amended its emergency use approval for REGEN-COV by restricting its use after citing its lack of efficacy against the Omicron variant. As a result, the antibody cocktail is not authorized or being sold in the U.S. outside of emergency use. 
Over the last 2 years, REGN has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 2 upward revisions and 11 downward. Revenue estimates have seen 7 upward revisions and 6 downward.
Shares of Regeneron (REGN) gained about 5% in early May after the company reported Q1 2022 results that beat estimates and a revenue figure that was boosted by sales of blockbuster drugs Eylea and Dupixent.
Focus for Q2 will once again be on Eylea sales. The injection is indicated to treat various eye-related disorders and brought in U.S. sales of $1.52B in Q1.
"(Eylea) sales in the second quarter are likely to have witnessed a sequential increase with growth in demand," Zacks research said on Friday. The Zacks consensus estimate for Q2 U.S. Eylea sales is $1.59B. 
Investors will also be looking at the revenue figure for REGN's other blockbuster drug, Dupixent, for which the company has a collaboration agreement with Sanofi (SNY).
SNY last week said Q2 sales of Dupixent grew 43.4% Y/Y to â¬1.96B.
"Label expansion of (Dupixent) in the past few months is likely to have boosted sales further and resulted in incremental revenues for Regeneron in the second quarter," Zacks research said.
Another important development during Q2 was Regeneron's (REGN) acquisition of worldwide exclusive license rights to cancer drug Libtayo from Sanofi (SNY). Investors will be looking out for the medicine's performance.
The Wall Street average rating and SA Authors rating on REGN is buy. However, Seeking Alpha's Quant rating system, which consistently beats the market, gives the stock a hold rating, with poor marks for growth.